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Editorial 
For laboratories with limited resources the economical study of Candida spp. biofilms 
tends to lend itself to unsophisticated models that negate the requirement for expert 
handling or the use of specialized equipment. Within these constraints, models that 
are readily amenable to high throughput screening are highly desirable and widely 
utilised. One key standardized high throughput model that has been extensively 
detailed is a 96 well microtitre plate format with flexibility to study the formation of 
biofilms and their antifungal susceptibilities (Ramage et al. 2001; Pierce et al. 2008). 
This has subsequently been adopted by a number of groups to evaluate various 
experimental parameters of biofilm formation (Ramage, Vande Walle et al. 2001; 
Thein et al. 2007; Tumbarello et al. 2007). Alongside this biofilm testing platform is a 
simple soluble formazan based bioassay that uses the metabolic dye XTT (2,3-bis 
(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) (Tellier et al. 
1992; Hawser 1996a), enabling a rapid and highly reproducible semi-quantitative 
assessment of biofilms (Hawser 1996b; Hawser et al. 1998; Ramage, Vande Walle 
et al. 2001). This colorimetric assay is non-invasive and non-destructive, requiring 
minimal post-processing of samples as compared to other alternative methods, such 
as viable cell counts that run into problems with cellular aggregates. Using this 
technique multiple microtitre plates can be processed simultaneously without 
compromising accuracy. However, whereas the XTT assay is useful for antifungal 
testing to evaluate the effects of the drug on a sessile population, in comparison to 
an untreated control, metabolic variability between different isolates and species, 
making its usefulness in quantifying biofilm development limited. Therefore, caution 
should be taken when interpreting the data obtained from this metabolic assay to 
assess biofilm formation (Kuhn et al. 2003; Taff et al. 2012).  
 
Recently there is an increasing wave of candidal biofilm research using a rapid 
screen of isolates with crystal violet (CV) based biomass assays and the metabolic 
dye XTT (Dhale et al. 2014; Marcos-Zambrano et al. 2014). These are used as a 
means of comparing multiple clinical isolates and species, particularly in relation to 
clinical outcomes (Tumbarello, Posteraro et al. 2007; Tumbarello et al. 2012; 
Rajendran et al. 2016). The recent study by Pongrácz and colleagues (2016) is worth 
considering in this context. In the paper entitled “in vitro biofilm production of Candida 
bloodstream isolates: any association with clinical characteristics?” (Pongrácz et al. 
2016). The authors used both CV and XTT to classify biofilm producers. However, 
there is no apparent criteria or basis for stratification. For example, the authors used 
OD490 for standard XTT concentrations, where values between 0.09 and 0.45 to 
denote low biofilm formers (LBF) and values ≥ 0.9 to denote high biofilm formers 
(HBF). Whereas, for CV an OD570 of ≥ 0.09 were simply considered biofilm 
producers. In contrast, Tumbranello and colleagues (2007) used both standard XTT 
methodology accompanied by spectrophotometric analysis (% transmittance), which 
was stratified using an ordinal scale (Tumbarello, Posteraro et al. 2007). Stratification 
was used to group non-biofilm formers, LBF and HBF, and to correlate with XTT 
readings. This group later used the same methodology, though stating that % 
transmittance of <10 equated to non-biofilm formers, and for XTT anything above an 
OD490 of 0.1 was a biofilm former (Tumbarello, Fiori et al. 2012). Finally, our own 
group used a similar approach to categorize isolates based three bioassays, XTT, 
SYTO 9 and CV biomass (OD570) values (Rajendran, Sherry et al. 2016). CV was 
finally used to stratify the clinical isolates tested, and those within the first quartile 
(Q1) were classed as LBF, isolates with a biomass greater than the third quartile 
(Q3) were classed as HBF, and those in between were classed as intermediate 
biofilm formers (IBF) (second quartile [Q2]). Clearly, a variety of different criteria are 
used in these published studies, but should we be guided by just one criterion? This 
is important if we are going to try as a community to correlate the clinical importance 
of candidal biofilm infections. 
 
For the novice entering the world of candidal biofilm research then these, or even the 
experienced, the plethora of papers taking differing approaches can be confusing,. 
Which of these quantitative methods is the most robust and reliable? Should I be 
comparing different species using these methods? Is there a defined number that 
differentiates biofilm from non-biofilm? Are there different levels of biofilm formation? 
Lack of clarity and standardization in the field makes answering these questions 
impossible, particularly as there are other permutations to consider such as choice of 
media, time of biofilm development, the specifics of their own quantification method, 
and of course the purpose of the experiment. Clearly, we do need some guidance 
that will allow those using these assays to undertake meaningful comparisons with 
the published literature. Having had the opportunity to publish and review in this field 
over the past 15 years or so then there are aspects that should be adhered to: 1) do 
not use XTT to compare different species due to variability in XTT readings (you are 
comparing apples and oranges), 2) understand the limitations of CV (the assay is not 
sensitive enough to differentiate subtle differences in biofilm formation, 3) when 
screening clinical isolates or any panel of isolates, take a belt and braces approach 
(one bioassay is not enough) and 4) understand your research question (the 
bioassay(s) you select to use is dictated by this).  
 There are many other do’s and don’ts when it comes to investigating candidal 
biofilms, but the one key pointer is to take a balanced approach and read both the 
contemporary and historical literature. Both are equally valuable, as we can see from 
the evolution of the subject area, but the early studies lay a solid foundation. One 
aspect remains constant however, the use of XTT as our primary tool. Remember its 
limitations though, and use the quantitative data produced in a meaningful way in 
order to detect important clinical correlations, that may be missed otherwise. 
Pongrácz and colleagues (2016) suggest from their analysis that biofilm formation is 
greater in non-albicans yeasts than C. albicans, and that biofilm production does not 
correlate with mortality (Pongrácz, Benedek et al. 2016), which is in contrast to 
similar recent study designs (Tumbarello, Fiori et al. 2012; Rajendran, Sherry et al. 
2016). We therefore need to ensure that in addition to having robust clinical data that 
due consideration is given to the accompanying technical analysis in defining the 
parameters of what really constitutes a Candida biofilm. 
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